Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Evaxion Biotech

Evaxion announces business update and third quarter 2024 financial results
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion Announces Business Update and Second Quarter 2024 Financial Results
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion Announces Business Update and First Quarter 2024 Financial Results
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion Announces Business Update and Full Year 2023 Financial Results
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion Announces Closing of $15 Million Public Offering
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion Biotech Announces Pricing of $15 Million Public Offering
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion Announces Completion of ADS Ratio Change
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion Announces Plan to Implement ADS Ratio Change
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion Biotech Announces Closing of Private Placement
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion Announces Business Update and Third Quarter 2023 Financial Results
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion Biotech Announces Private Placement Financing
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presented
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion announces Executive Management Changes to strengthen the AI-strategy
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion Announces Business Update and Second Quarter 2023 Financial Results
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion announces financing commitments totaling up to USD 20 million with Negma Group
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus
From Evaxion Biotech
Via GlobeNewswire
Tickers EVAX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.